



# Integrative analysis of mitochondrial changes in Parkinson's disease

Enrico Glaab  
*Luxembourg Centre for Systems Biomedicine*

---

# Outline

- Approach for algorithmic biospecimen selection & matching
- Overview of updated PD omics data collection
- Integrated meta-analysis of PD GWAS and transcriptomics data

# Algorithmic biospecimen selection & matching

---



**GOAL:** Find a selection for a given number of **IPD patients** and **controls**, such that

- **Genders** are matched and balanced
- **Age** distributions are matched
- **BMI** distributions are matched
- Occurrence of **hypertension** / use of **arterial medication** is balanced
- Occurrence of other **comorbidities** is reduced and approx. balanced
- Further optional criteria, e.g. focus on **de novo patients** or **early treatment period**

**BENEFITS:** → Reduces influence of confounding factors on omics analyses  
→ Removes unwanted sources of variance

# Matched sample selection (LuxPARK blood profiling study)

- **Gender representation:** PD (20 females, 20 males), controls (20 females, 20 males)
- **Arterial medication:** PD (7), controls (6 + 2 unknown)
- **Medication for other symptoms:** PD (6 unknown), controls (1 + 2 unknown)
- **Maximum number of de novo patients included**



# Current collection of human PD datasets

Data type	Conditions	Data source
Transcriptomics (Whole blood)*	PD (298), control (331)	DeNoPa, GENEPAK, GEO
Transcriptomics (Substantia nigra)*	PD (92), control (88)	GEO
Metabolomics (Blood plasma)	GC-MS: PD (112), control (65), LC-MS: PD (89), control (90)	DeNoPa, PPMI, Cologne/Marburg
Metabolomics (CSF)	GC-MS: PD (44), control (43)	DeNoPa, PPMI
Resting-state fMRI + FDG/FDOPA PET subsets	PD (149), control (36)	PPMI, Cologne/Marburg
Clinical Data	PD (565), control (590), other (96); PD (159), control (110), other (3); PD (454), control (215), SWEDD (81);	LuxPARK, DeNoPa, PPMI
GWAS†	PD (28,818), control (1,039,955)	dbGAP
Exomes	PD (391), SWEDD (60), control (178)	PPMI

\*after filtering out samples failing in  $\geq 2$  quality tests (ArrayQuality metrics software) †after quality filtering

# Collection of PD GWAS datasets for meta-analysis

## GWAS data overview:

Study	Conditions	Platform
<b>TREND</b>	PD (1, 298), control (883)	NeuroX chip
<b>LANDSCAPE</b> (Dutch cohort)	PD (772), control (2024)	Illumina Human660W-Quad beadchip
<b>PPMI</b>	PD (383), SWEDD (58), control (178)	NeuroX chip
<b>Nalls et al.</b> , Nat. Genet., 2014 (pre-processed data from 15 independent GWAS datasets of European descent)	PD (13,708), control (95,282)	Multiple Illumina GWAS platforms


# Mitochondrial genes in the meta-analysis of GWAS data

Determine mitochondrial genes containing SNPs with putative PD associations from the **meta-analysis of GWAS datasets** ( $p < 1E-05$ , MitoFDR  $< 0.3$ )

Gene Symbol	Description	MitoFDR
MCCC1*†	methylcrotonoyl-CoA carboxylase 1 (alpha)	0
MALSU1	mitochondrial assembly of ribosomal large subunit 1	0
SLC25A20	Solute Carrier Family 25 Member 20	0
NDUFAF2	NADH dehydrogenase (ubiquinone) complex I, assembly factor 2	0.01
SPATA19	spermatogenesis associated 19	0.012
ABCB9†‡	ATP-binding cassette, sub-family B (MDR/TAP), member	0.036
DNAH17	dynein axonemal heavy chain 17	0.071
QARS‡	Glutaminyl-TRNA Synthetase	0.077
NSF†‡	N-ethylmaleimide sensitive factor, vesicle fusing ATPase	0.101
PPT2‡	palmitoyl-protein thioesterase 2	0.119
NAGLU†	N-acetyl-alpha-glucosaminidase	0.15
TUBG1‡	Tubulin Gamma 1	0.199
C2	Complement C2	0.227
FDFT1†	farnesyl-diphosphate farnesyltransferase 1	0.232
VARS†‡	valyl-tRNA synthetase	0.239
FKBPL	FK506 binding protein like	0.267

\*previously shown to contain genome-wide significant SNPs, Nalls et al., 2014  
Differentially expressed in transcriptomics meta-analysis: †whole-blood, ‡brain

# Acknowledgements



## Collaborators:

- **NCER-PD Team: Reinhard Schneider, Rejko Krüger, Ines Thiele, Ronan Fleming**
- **Jens Schwamborn**
- **Carole Linster**
- **Anne Grünewald**
- **Antonio del Sol**
- **Jorge Goncalves**
- **Alex Skupin**
- **Alexander Crawford**

## Funding support:



Fonds National de la  
Recherche Luxembourg



**BrightFocus™**  
Foundation

Cure in Mind. Cure in Sight.



FONDATION  
DE LUXEMBOURG  
Philanthropy in action



**JPND**  
research

EU Joint Programme – Neurodegenerative Disease Research



**GEOFFREY BEENE  
FOUNDATION**  
ALZHEIMER'S INITIATIVE



# References

1. E. Glaab, *Using prior knowledge from cellular pathways and molecular networks for diagnostic specimen classification*, Briefings in Bioinformatics (2015), 17(3), pp. 440
2. E. Glaab, R. Schneider, *Comparative pathway and network analysis of brain transcriptome changes during adult aging and in Parkinson's disease*, Neurobiology of Disease (2015), 74, 1-13
3. N. Vlassis, E. Glaab, *GenePEN: analysis of network activity alterations in complex diseases via the pairwise elastic net*, Statistical Applications in Genetics and Molecular Biology (2015), 14(2), 221
4. S. Köglberger, M. L. Cordero-Maldonado, P. Antony, J. I. Forster, P. Garcia, M. Buttini, A. Crawford, E. Glaab, *Gender-specific expression of ubiquitin-specific peptidase 9 modulates tau expression and phosphorylation: possible implications for tauopathies*, Molecular Neurobiology (2016), in press (doi: 10.1007/s12035-016-0299-z)
5. L. Grandbarbe, S. Gabel, E. Koncina, G. Dorban, T. Heurtaux, C. Birck, E. Glaab, A. Michelucci, P. Heuschling, *Inflammation promotes a conversion of astrocytes into neural progenitor cells via NF- $\kappa$ B activation*, Molecular Neurobiology (2016), Vol. 53, No. 8, 5041-5055
6. S. Kleiderman, J. Sá, A. Teixeira, C. Brito, S. Gutbier, L. Evje, M. Hadera, E. Glaab, M. Henry, S. Agapios, P. Alves, U. Sonnewald, M. Leist, *Functional and phenotypic differences of pure populations of stem cell-derived astrocytes and neuronal precursor cells*, Glia (2016), Vol. 64, No. 5, 695-715
7. E. Glaab, R. Schneider, *RepExplore: Addressing technical replicate variance in proteomics and metabolomics data analysis*, Bioinformatics (2015), 31(13), pp. 2235
8. E. Glaab, *Building a virtual ligand screening pipeline using free software: a survey*, Briefings in Bioinformatics (2015), 17(2), pp. 352
9. E. Glaab, A. Baudot, N. Krasnogor, R. Schneider, A. Valencia. *EnrichNet: network-based gene set enrichment analysis*, Bioinformatics, 28(18):i451-i457, 2012
10. E. Glaab, R. Schneider, *PathVar: analysis of gene and protein expression variance in cellular pathways using microarray data*, Bioinformatics, 28(3):446-447, 2012
11. E. Glaab, J. Bacardit, J. M. Garibaldi, N. Krasnogor, *Using rule-based machine learning for candidate disease gene prioritization and sample classification of cancer gene expression data*, PLoS ONE, 7(7):e39932, 2012
12. E. Glaab, A. Baudot, N. Krasnogor, A. Valencia. *TopoGSA: network topological gene set analysis*, Bioinformatics, 26(9):1271-1272, 2010
13. E. Glaab, A. Baudot, N. Krasnogor, A. Valencia. *Extending pathways and processes using molecular interaction networks to analyse cancer genome data*, BMC Bioinformatics, 11(1):597, 2010
14. E. Glaab, J. M. Garibaldi and N. Krasnogor. *ArrayMining: a modular web-application for microarray analysis combining ensemble and consensus methods with cross-study normalization*, BMC Bioinformatics, 10:358, 2009
15. E. Glaab, J. M. Garibaldi, N. Krasnogor. *Learning pathway-based decision rules to classify microarray cancer samples*, German Conference on Bioinformatics 2010, Lecture Notes in Informatics (LNI), 173, 123-134
16. E. Glaab, J. M. Garibaldi and N. Krasnogor. *VRMLGen: An R-package for 3D Data Visualization on the Web*, Journal of Statistical Software, 36(8), 1-18, 2010
17. C. Jaeger, E. Glaab, A. Michelucci, T. M. Binz, S. Koeglsberger, P. Garcia, J. P. Trezzi, J. Ghelfi, R. Balling, M. Buttini, *The Mouse Brain Metabolome: Region-Specific Signatures and Response to Excitotoxic Neuronal Injury*, American Journal of Pathology (2015), Vol. 185, No. 6, pp. 1699